ARTICLE | Company News
Savient sales and marketing update
December 6, 2010 8:00 AM UTC
Savient launched Krystexxa pegloticase in the U.S. to treat chronic gout. The wholesale acquisition cost (WAC) for an 8 mg IV dose of the pegylated urate oxidase given every two weeks is $2,300. ...